Web Analytics

3 Latest Announced Rounds

  • $1,200,000
    Pre-Seed

    2 Investors

    Technology, Information and Internet
    Dec 4th, 2024
  • $10,400,000
    Unknown

    1 Investors

    Wellness and Fitness Services
    Dec 4th, 2024
  • $9,561,279
    Seed

    2 Investors

    Biotechnology Research
    Dec 4th, 2024
$417.35M Raised in 36 Funding Rounds in the past 7 Days - View All

Funding Round Profile

MimiVax, LLC

start up
United States - Buffalo, NY
  • 10/12/2021
  • Unknown
  • $5,000,000

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates

MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer.

SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2 clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) as well as Phase 1 in Neuro-Endocrine Tumors (NET)


Related People

Michael CiesielskiFounder

Michael Ciesielski United States - Buffalo-Niagara Falls Area

At MimiVax, our mission is to disrupt cancer. To increase survival and send hope through the development of highly innovative immunotherapies aimed at improving patient's lives.